Every Form 4 that Cue Biopharma Inc (CUE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CUE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CUE filings page.
Cue Biopharma, Inc. (symbol: CUE) is the issuer of record for a Form 4/A filing submitted to the SEC.
Cue Biopharma, Inc. (CUE) reports an amended Form 4 for director Pamela Garzone to correct a prior administrative calculation error in a grant of restricted stock units (RSUs). The original report showed 21,800 shares acquired; the correct amount is 18,900 shares, which is now also the total beneficially owned following the transaction. One-third of these RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to her continued service with the company.
Cue Biopharma, Inc. officer Sumita Ray reported a derivative PSU exercise and related share sales on August 13, 2026. A block of 18,196 common shares was issued upon settlement of performance stock units, while a matched 18,196 underlying derivative position was exercised and disposed.
To fund tax withholding from this vesting, Ray reported sell-to-cover transactions totaling 8,829 shares, including 2,383 shares at a weighted average price of $29.37 (range $28.97–$29.96), 6,442 shares at a weighted average price of $30.35 (range $29.99–$30.97), and 4 shares at $31.13. The PSUs vest in three equal tranches tied to stock-price targets of $33.00, $38.50, and $44.00 achieved over five consecutive trading days within 24 months of grant; one-third settled on August 13, 2026, with the remaining two-thirds expected to settle upon achievement of the higher targets.
Cue Biopharma, Inc. (CUE) officer Michael Vincent Meluzio reported equity compensation activity and related tax sales. He exercised performance stock units, receiving 13,647 shares of Common Stock, and sold 5,628 shares on August 13, 2026 in block trades used to cover tax withholding obligations through a non-discretionary sell-to-cover arrangement. The exercised award represents one-third of a PSU grant tied to stock-price targets, with the remaining two-thirds eligible to settle only if higher share-price hurdles are achieved within a specified performance period.
Cue Biopharma, Inc.’s Chief Executive Officer Shao-Lee Lin reported transactions in Common Stock linked to equity awards. On August 12, 2026, 109,179 performance stock units vested and settled into common shares, representing the first third of a PSU award tied to stock-price hurdles. On August 12–13, 2026, Lin sold an aggregate 58,258 shares at weighted-average prices between $26.50 and $29.87; footnotes state these were block trades executed as “sell-to-cover” transactions to satisfy tax withholding obligations on restricted stock unit vesting and are not discretionary trades. The remaining two-thirds of the PSU award may settle upon achieving closing share prices of $38.50 and $44.00 for five consecutive trading days within 24 months of grant.
Cue Biopharma, Inc. granted Chief Financial Officer James M. Ahlers two equity awards on July 30, 2026: a stock option for 51,000 shares of common stock at an exercise price of $30.40 per share, expiring July 30, 2036, and 25,500 restricted stock units. Both the option and RSUs vest in equal quarterly installments over four years from July 30, 2026, subject to his continued service with the company through each vesting date.
Cue Biopharma Chief Executive Officer Shao-Lee Lin, through the Shao-Lee Lin Trust dated March 13, 2023, reported acquiring 90,906 pre-funded warrants and 45,453 common stock warrants on June 1, 2026. These securities were issued in a private placement under an April 30, 2026 securities purchase agreement at $11.00 per pre-funded warrant plus accompanying half-share warrant. The pre-funded warrants have a $0.001 exercise price and no expiration; the common stock warrants have an $11.00 exercise price and expire on May 4, 2031. Both series became exercisable on June 1, 2026 after stockholder approval, and the board approved the transactions under Rule 16b-3. The amendment corrects only the previously reported transaction code.
Cue Biopharma, Inc. granted its Chief Medical Officer and Head of Research & Development, Dominique Christian Borie, 31,500 restricted stock units (RSUs) and stock options for 63,000 shares of common stock. The options carry an exercise price of $30.9200 per share and expire on July 13, 2036.
The RSUs and options each vest in equal quarterly installments over four years starting July 13, 2026, contingent on Borie’s continued service with the company. Following these grants, Borie holds 31,500 common shares and options on 63,000 shares directly.
Garzone Pamela reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. reported that director Pamela Garzone received a grant of 21,800 shares of Common Stock in the form of restricted stock units. One-third of the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, contingent on her continued service with the company. Following this equity award, she holds 21,800 shares directly.
Camardo Daniel A. reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. reported that director Daniel A. Camardo received a grant of 21,800 shares of Common Stock in the form of restricted stock units. One-third of these RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to his continued service with the company. Following this award, he holds 21,800 shares of Common Stock directly.
Sarraf Pasha reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. director Sarraf Pasha received a grant of 21,800 restricted stock units (RSUs) of common stock. One-third of these RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to continued service. Following this award, Pasha holds 32,595 shares (on a post–1-for-30 reverse split basis effective April 22, 2026).
Meehan Viola Mong reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. director Meehan Viola Mong received an equity compensation award of 21,800 shares of Common Stock in the form of restricted stock units. The RSUs were granted at a stated price of $0.00 per share and are held directly. One-third of the shares underlying the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to continued service with the company through each vesting date. Following this award, the reporting person holds 21,800 shares of Common Stock.
Cue Biopharma, Inc. reported an equity compensation grant to officer Michael Vincent Meluzio, VP and Principal Accounting Officer. He received 40,942 shares of common stock through restricted stock units that vest in equal quarterly installments over 48 months from the grant date, conditioned on continued service. He also received a separate grant of 40,942 performance stock units that may convert into common shares only if the stock trades at or above $33.00, $38.50, and $44.00 for five consecutive trading days for each tranche within 24 months, after which any unmet tranches are forfeited.
Ray Sumita reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. granted Chief Legal Compliance Officer and Corporate Secretary Sumita Ray a total of 109,178 shares tied to equity awards on July 9, 2026. The awards comprise 54,589 restricted stock units (RSUs) vesting in equal quarterly installments over 48 months and 54,589 performance stock units (PSUs) that vest in three tranches only if stock-price targets of $33.00, $38.50 and $44.00 are each maintained for five consecutive trading days by 24 months from grant, otherwise the PSUs are forfeited.
Lin Shao-Lee reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. reported that Chief Executive Officer Shao-Lee Lin received equity awards covering 327,537 shares of Common Stock on July 9, 2026. The awards consist of restricted stock units and performance stock units, and Lin now holds 655,074 Common shares directly following these grants.
Cue Biopharma, Inc. reported that director Daniel A. Camardo received a grant of stock options covering 1,626 shares of common stock. The options have an exercise price of $21.90 per share and expire on May 29, 2036.
The award vests over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in eight equal quarterly installments. Following this grant, Camardo holds stock options for 1,626 underlying shares directly as reported in this filing.
Cue Biopharma, Inc. director and Chief Executive Officer Shao-Lee Lin reported indirect purchases of derivative securities tied to the company’s common stock. A trust associated with Lin acquired 45,453 common stock warrants with an exercise price of $11.00 per share and 90,906 pre-funded warrants with an exercise price of $0.001 per share on June 1, 2026.
These positions were obtained under a securities purchase agreement entered on April 30, 2026, in a private placement that closed on May 4, 2026. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following stockholder approval of the underlying common stock issuance at the company’s Special Meeting of Stockholders in accordance with Nasdaq listing rules.
Cue Biopharma director Viola Mong received a new stock option grant as part of her compensation. She was awarded options covering 1,626 shares of common stock at an exercise price of $21.90 per share. These options vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in eight equal quarterly installments, aligning her incentives with the company’s long-term performance.
Cue Biopharma CEO Shao-Lee Lin reported equity awards on Common Stock. Lin received 327,537 shares of Common Stock and a stock option for 655,074 shares at an exercise price of $30.42 per share, vesting in 48 equal monthly installments beginning on April 30, 2026.
Cue Biopharma, Inc. reported that SVP and General Counsel Colin Sandercock received a grant of stock options on Common Stock. The award covers 200,000 stock options with an exercise price of $0.29 per share and an expiration date of April 8, 2036.
These options vest over four years, with 25% vesting on the one-year anniversary of the grant date and the remaining options vesting in equal semi-annual installments thereafter. Following this grant, Sandercock holds 200,000 stock options directly, reflecting a routine compensation-related equity award rather than an open-market transaction.
Cue Biopharma, Inc. reported that Chief Business Officer Lucinda Warren received a grant of stock options covering 250,000 shares of common stock. The options have an exercise price of $0.29 per share and expire on April 8, 2036.
The award vests over four years, with 25% vesting on the first anniversary of the grant date and the remaining options vesting in equal semi-annual installments thereafter. Following this grant, Warren holds 250,000 stock options directly.
Cue Biopharma, Inc. reported that Chief Development Officer Daniel G. Baker received a grant of stock options covering 100,000 shares of Common Stock. The options have an exercise price of $0.29 per share and expire on April 8, 2036.
The award vests over four years, with 25% of the options vesting on the first anniversary of the grant date and the remaining options vesting in equal semi-annual installments thereafter. Following this grant, Baker holds 100,000 stock options directly.
Cue Biopharma director Peter A. Kiener reported a new stock option grant dated 01/02/2026. He received a stock option for 24,400 shares of Cue Biopharma common stock with an exercise price of $0.34 per share, recorded as an acquisition of derivative securities. The option was granted under the company’s Director Compensation Policy and is scheduled to become fully exercisable on the first anniversary of the grant date, with an expiration date of 01/01/2036. Following this grant, Kiener beneficially owns 24,400 stock options directly.
Cue Biopharma, Inc. reported a routine insider transaction showing a stock option grant to director Pamela Garzone. On 01/02/2026, she received 24,400 stock options with an exercise price of $0.34 per share. According to the disclosure, the award was granted under the company’s Director Compensation Policy.
The filing states that this stock option becomes fully exercisable on the first anniversary of the grant date and carries an expiration date of 01/01/2036. Following this grant, Garzone beneficially owns 24,400 derivative securities directly, reflecting only this option award.
Cue Biopharma director Sarraf Pasha reported receiving a stock option award from the company. On 01/02/2026, Pasha was granted an option to buy 24,400 shares of Cue Biopharma common stock at an exercise price of $0.34 per share, with no cash paid for the grant itself. The award was made under the company’s Director Compensation Policy.
The filing states that this option becomes fully exercisable on the first anniversary of the grant date and carries an expiration date of 01/01/2036. Following this grant, Pasha beneficially owns 24,400 derivative securities in the form of these stock options, held directly.
Cue Biopharma, Inc. (CUE) reported a Form 4 transaction for its Chief Business Officer. The officer received a stock option grant covering 125,000 shares of Cue Biopharma common stock on 09/29/2025. The option has an exercise price of $0.72 per share and expires on 09/28/2035.
According to the filing, this stock option becomes fully exercisable on the first anniversary of the grant date, meaning the officer must wait one year before the option is fully vested. Following this grant, the officer beneficially owns 125,000 derivative securities, held directly. This transaction reflects equity-based compensation designed to align the officer’s interests with those of shareholders.
Cue Biopharma, Inc. (CUE) reported an equity award to its chief development officer. The reporting person received a stock option covering 50,000 shares of common stock at an exercise price of $0.72 per share on 09/29/2025. This option is scheduled to become fully exercisable on the first anniversary of the grant date and carries an expiration date of 09/28/2035. After this grant, the reporting person holds 50,000 derivative securities related to Cue Biopharma common stock with direct ownership.
Cue Biopharma director and CEO Usman Azam was granted a stock option on 09/29/2025 to purchase 1,875,000 shares of common stock at an exercise price of $0.72 per share. The option was reported on Form 4 filed 10/02/2025 and becomes exercisable in 48 monthly installments beginning 09/29/2026, with an expiration date of 09/28/2035. After the grant, Azam beneficially owns 1,875,000 underlying shares directly. The filing was signed by an attorney-in-fact on Azam's behalf.